中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 9
Sep.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(9): 2046-2052

Application of the three-dimensional visualization ablation planning system in radiofrequency ablation for hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2022.09.019

  • Department of General Surgery, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China

Research funding:

The Science and Technology Plan of the Beijing Education Committee (KM201710025026)

More Information
  • Corresponding author: ZHANG Ke, zhangke302@sina.com(ORCID: 0000-0002-5006-8674)
  • Received Date: 2022-02-09
  • Accepted Date: 2022-03-23
  • Published Date: 2022-09-20
    Abstract
  •   Objective  To investigate the significance of the three-dimensional visualization ablation planning system in radiofrequency ablation for liver cancer.  Methods  A total of 71 patients who received radiofrequency ablation for hepatocellular carcinoma in Beijing Ditan Hospital, Capital Medical University from July 2017 to December 2020 were enrolled as subjects. The 34 patients in the three-dimensional group used the three-dimensional visualization ablation planning system for radiofrequency protocol planning before surgery and the 37 patients in the two-dimensional group used the two-dimensional image for radiofrequency protocol planning before surgery. The two groups were compared in terms of the indices such as the first-attempt success rate of puncture, complete tumor ablation rate, and tumor-free survival. The Fisher's exact test, the chi-square test of continuous correction, or the Pearson chi-square test was used for comparison of categorical data between two groups; the t-test was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups. The Kaplan-Meier method was used to plot survival curves, and the Log-rank (Mantel-Cox) test was used for comparison of tumor recurrence and survival; the Cox proportional-hazards regression model analysis was used to investigate the influencing factors for tumor-free survival.  Results  Compared with the two-dimensional group, the three-dimensional group had a significantly higher first-attempt success rate of puncture (94.12% vs 75.68%, Pearson χ2=4.183, P=0.041) and a significantly shorter median time of puncture (5 minutes vs 7 minutes, Z=-2.407, P=0.013). There was no significant difference in complete ablation rate between the three-dimensional group and the two-dimensional group (97.06% vs 91.89%, continuous correction χ2=0.183, P=0.669). There were significant differences in the 1-, 2-, and 4-year cumulative tumor-free survival rates between the three-dimensional group and the two-dimensional group (90.8%/78.8%/72.8% vs 61.5%/55.9%/44.7%, χ2=5.073, P=0.024). The multivariate Cox regression analysis showed that preoperative planning method, complete or incomplete ablation, and alpha-fetoprotein at 1 month after surgery were independent influencing factors for the tumor-free survival of patients with liver cancer after radiofrequency ablation (all P < 0.05).  Conclusion  Radiofrequency ablation planning via the three-dimensional visualization ablation planning system can ensure the therapeutic effect of radiofrequency ablation, reduce the recurrence rate of liver cancer, and prolong the tumor-free survival of patients.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359- E386. DOI: 10.1002/ijc.29210.
    [2]
    YUAN SX, ZHOU WP. Progress and hot spots of comprehensive treatment for primary liver cancer[J]. Chin J Dig Surg, 2021, 20(2): 163-170. DOI: 10.3760/cma.j.cn115610-20201211-00776.

    袁声贤, 周伟平. 原发性肝癌综合治疗的进展和热点[J]. 中华消化外科杂志, 2021, 20(2): 163-170. DOI: 10.3760/cma.j.cn115610-20201211-00776.
    [3]
    ZHOU M, WANG H, ZENG X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158. DOI: 10.1016/S0140-6736(19)30427-1.
    [4]
    Bureau of Medical Administration, National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.

    中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
    [5]
    European Association for the Study of the Liver. EASL clinical practice guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. DOI: 10.1016/j.jhep.2018.03.019.
    [6]
    ZHU F, RHIM H. Thermal ablation for hepatocellular carcinoma: what's new in 2019[J]. Chin Clin Oncol, 2019, 8(6): 58. DOI: 10.21037/cco.2019.11.03.
    [7]
    LI R, CHEN HP, WANG F, et al. Application of contrast-enhanced ultrasound combined with percutaneous radiofrequency ablation in treatment of liver cancer rupture and bleeding[J]. Chin J Gerontol, 2020, 40(17): 3653-3656. DOI: 10.3969/j.issn.1005-9202.2020.17.021.

    李锐, 陈卉品, 王菲, 等. 超声造影联合经皮射频消融在肝癌破裂出血治疗中的应用[J]. 中国老年学杂志, 2020, 40(17): 3653-3656. DOI: 10.3969/j.issn.1005-9202.2020.17.021.
    [8]
    ZHI-YU H, PING L, XIAO-LING Y, et al. A clinical study of thermal monitoring techniques of ultrasound-guided microwave ablation for hepatocellular carcinoma in high-risk locations[J]. Sci Rep, 2017, 7: 41246. DOI: 10.1038/srep41246.
    [9]
    HUANG S, YU J, LIANG P, et al. Percutaneous microwave ablation for hepatocellular carcinoma adjacent to large vessels: a long-term follow-up[J]. Eur J Radiol, 2014, 83(3): 552-558. DOI: 10.1016/j.ejrad.2013.12.015.
    [10]
    CAO F, FAN WJ. Ablation therapy for large hepatocellular carcinoma[J]. J Clin Hepatol, 2021, 37(3): 501-505. DOI: 10.3969/j.issn.1001-5256.2021.03.002.

    曹飞, 范卫君. 大肝癌的消融治疗[J]. 临床肝胆病杂志, 2021, 37(3): 501-505. DOI: 10.3969/j.issn.1001-5256.2021.03.002.
    [11]
    HU H, CHEN GF, YUAN W, et al. Microwave ablation with chemoembolization for large hepatocellular carcinoma in patients with cirrhosis[J]. Int J Hyperthermia, 2018, 34(8): 1351-1358. DOI: 10.1080/02656736.2018.1462536.
    [12]
    FANG CH, ZHANG P, ZHOU WP, et al. Efficacy of three-dimensional visualization technology in the precision diagnosis and treatment for primary liver cancer: a retrospective multicenter study of 1 665 cases in China[J]. Chin J Surg, 2020, 58(5): 375-382. DOI: 10.3760/cma.j.cn112139-20200220-00105.

    方驰华, 张鹏, 周伟平, 等. 三维可视化技术用于1665例原发性肝癌精准诊治的多中心回顾性研究[J]. 中华外科杂志, 2020, 58(5): 375-382. DOI: 10.3760/cma.j.cn112139-20200220-00105.
    [13]
    BARI H, WADHWANI S, DASARI B. Role of artificial intelligence in hepatobiliary and pancreatic surgery[J]. World J Gastrointest Surg, 2021, 13(1): 7-18. DOI: 10.4240/wjgs.v13.i1.7.
    [14]
    YEO CT, MACDONALD A, UNGI T, et al. Utility of 3D reconstruction of 2D liver computed tomography/magnetic resonance images as a surgical planning tool for residents in liver resection surgery[J]. J Surg Educ, 2018, 75(3): 792-797. DOI: 10.1016/j.jsurg.2017.07.031.
    [15]
    LI SS, ZHANG K, CHENG SJ, et al. Current status and future perspectives of the application of medical 3D visualization technology in accurate surgery of liver tumors[J]. J Clin Hepatol, 2019, 35(5): 1114-1117. DOI: 10.3969/j.issn.1001-5256.2019.05.042.

    李山山, 张珂, 程树杰, 等. 医学三维可视化技术在肝肿瘤精准手术中的应用现状及展望[J]. 临床肝胆病杂志, 2019, 35(5): 1114-1117. DOI: 10.3969/j.issn.1001-5256.2019.05.042.
    [16]
    HU M, HU H, CAI W, et al. The safety and feasibility of three-dimensional visualization technology assisted right posterior lobe allied with part of V and VⅢ sectionectomy for right hepatic malignancy therapy[J]. J Laparoendosc Adv Surg Tech A, 2018, 28(5): 586-594. DOI: 10.1089/lap.2017.0479.
    [17]
    RENZULLI M, TOVOLI F, CLEMENTE A, et al. Ablation for hepatocellular carcinoma: beyond the standard indications[J]. Med Oncol, 2020, 37(4): 23. DOI: 10.1007/s12032-020-01348-y.
    [18]
    YOSHIDA S, KORNEK M, IKENAGA N, et al. Sublethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma[J]. Hepatology, 2013, 58(5): 1667-1680. DOI: 10.1002/hep.26526.
    [19]
    CROCETTI L, de BAÉRE T, PEREIRA PL, et al. CIRSE standards of practice on thermal ablation of liver tumours[J]. Cardiovasc Intervent Radiol, 2020, 43(7): 951-962. DOI: 10.1007/s00270-020-02471-z.
    [20]
    YANG JD, HAINAUT P, GORES GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(10): 589-604. DOI: 10.1038/s41575-019-0186-y.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(5)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (286) PDF downloads(124) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return